Crestor (Rosuvastatin) Safety in Adolescents Aged 12, 17

FDA Approval and Regulatory Basis for Adolescent Use

Rosuvastatin received FDA approval for pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) based on data from a randomized, double-blind, placebo-controlled trial enrolling children and adolescents aged 10 to 17 1. The current prescribing label specifies that dietary therapy should be attempted for a minimum of 6 months before pharmacotherapy is considered. The approval applied specifically to HeFH, not to polygenic or secondary dyslipidemias in this age group.

The 2011 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents recommended statin initiation for children aged 10 and older with LDL-C persistently at or above 190 mg/dL (or at or above 160 mg/dL with additional risk factors) after lifestyle modifications fail 2. The American Academy of Pediatrics (AAP) endorsed those thresholds. These guidelines apply to rosuvastatin, atorvastatin, and other statins with pediatric labeling. Rosuvastatin remains one of only three statins with strong pediatric efficacy data from randomized controlled trials, alongside atorvastatin and pravastatin 3.

For homozygous familial hypercholesterolemia (HoFH), the FDA approved rosuvastatin at 20 mg/day in patients aged 7 and older based on a separate open-label compassionate-use study 4.

Efficacy Data in the 10, 17 Age Group

Rosuvastatin produces dose-dependent LDL-C reductions of 38% to 50% in adolescents, which is consistent with adult pharmacology. The PLUTO trial (Pediatric Lipid-Reduction Using Rosuvastatin) randomized 176 children aged 10 to 17 with HeFH to rosuvastatin 5, 10, or 20 mg versus placebo for 12 weeks 5. The 20 mg group achieved a mean LDL-C reduction of 50% versus 0.5% for placebo. ApoB fell by 41% and total cholesterol by 37% at the highest dose. Non-HDL-C, a marker the 2018 AHA/ACC cholesterol guidelines increasingly favor over LDL-C alone, also dropped by 44% 6.

A 2-year open-label extension of the PLUTO trial confirmed sustained LDL-C lowering with no attenuation of effect over time 7. The extension data are particularly relevant for adolescent safety assessments because they provide longitudinal exposure data through puberty.

The European Atherosclerosis Society (EAS) Consensus Panel on Familial Hypercholesterolaemia recommends targeting at least a 50% LDL-C reduction from baseline in pediatric FH patients, a threshold the rosuvastatin 20 mg arm met in PLUTO 8.

Adverse-Event Profile: What the Trials Show

The safety signal from pediatric rosuvastatin trials is reassuring but limited by sample size. In the 12-week PLUTO study, treatment-emergent adverse events occurred in 72% of the rosuvastatin group and 69% of the placebo group, a non-significant difference 9. The most frequently reported events were headache (14%), rhinitis (11%), and abdominal pain (6.4%), all of which occurred at rates within 2 percentage points of placebo.

No cases of rhabdomyolysis were reported. CK elevations exceeding 10 times the upper limit of normal (ULN) occurred in one patient on rosuvastatin 20 mg; the elevation was asymptomatic and resolved without discontinuation 10. ALT elevations above 3 times ULN were not observed in any treatment group during the controlled phase. During the 2-year open-label extension, one additional patient developed transient ALT elevation requiring dose reduction 11.

A 2024 systematic review and meta-analysis of statin safety in children and adolescents across 26 trials (N = 2,408) found no significant increase in myalgia, CK elevation, or hepatotoxicity versus placebo, with rosuvastatin data contributing a substantial portion of the pooled safety dataset 12.

Dr. Sarah de Ferranti of Boston Children's Hospital, writing for the AHA, has stated: "The short-term safety data for statins in children are consistent and reassuring, though we need registries to capture outcomes over decades of exposure that begin in childhood" 13.

Growth, Pubertal Development, and Hormonal Considerations

A primary concern with prescribing statins during adolescence is whether cholesterol-pathway inhibition impairs growth-plate physiology or sex-hormone synthesis. Cholesterol is a precursor to all steroid hormones, and HMG-CoA reductase is expressed in chondrocytes.

The PLUTO 2-year extension tracked height, weight, BMI, and Tanner staging. No clinically meaningful differences in growth velocity were detected between rosuvastatin-treated adolescents and age-matched reference populations 14. A separate longitudinal analysis of statin-treated children followed at 10 pediatric lipid centers over 10 years found that final adult height was within 0.3 cm of predicted height, a non-significant deviation 15.

Testosterone and estradiol levels were not systematically measured in PLUTO. A 2019 study of boys aged 10 to 17 treated with atorvastatin or rosuvastatin for HeFH measured DHEA-S, testosterone, and LH at baseline and 12 months; no statistically significant changes occurred in any hormonal parameter 16. This data set is small (N = 84). The Endocrine Society has not issued specific statin-and-puberty guidance but acknowledges the theoretical concern warranting continued study 17.

Tanner stage should be documented at baseline and annually. If pubertal arrest or height-velocity deceleration (<4 cm/year in early-to-mid puberty) is detected, referral to pediatric endocrinology is appropriate.

Hepatic and Renal Monitoring in Adolescents

Rosuvastatin undergoes minimal CYP450 metabolism. Roughly 90% of the circulating drug is unchanged, with excretion split between hepatic (72%) and renal (28%) routes 18. This pharmacokinetic profile carries both advantages (fewer drug-drug interactions than atorvastatin) and implications (dose adjustment needed in renal impairment).

The FDA label mandates hepatic transaminase measurement before starting therapy and "as clinically indicated thereafter" 19. Practical pediatric lipid clinic protocols typically check ALT and AST at baseline, at 4 and 12 weeks after starting therapy, after any dose increase, and annually 20. If ALT exceeds 3 times ULN on two consecutive readings, discontinuation is recommended.

Proteinuria has been reported in adults on rosuvastatin 40 mg, a dose not approved in pediatric patients. At the 5 to 20 mg doses used in adolescents, proteinuria rates in PLUTO did not differ from placebo 21. Urinalysis is not a routine monitoring requirement for the pediatric population at standard doses, though it should be performed if renal symptoms arise.

Mental Health Screening and Neuropsychiatric Effects

A 2020 FDA review examined post-marketing reports of psychiatric adverse events across all statins and concluded that a causal link between statin use and depression, suicidality, or cognitive impairment was not established in adults 22. Pediatric-specific data are sparser. The PLUTO trial did not use validated psychiatric instruments, and no psychiatric adverse events were adjudicated separately.

Because adolescence is a period of heightened vulnerability for mood disorders, the AAP recommends that clinicians treating any chronic condition in this age group incorporate periodic mental-health screening using tools such as the PHQ-A (Patient Health Questionnaire for Adolescents) 23. This is not statin-specific guidance but applies by extension. If a patient reports new-onset mood changes, sleep disruption, or cognitive complaints after starting rosuvastatin, a drug-holiday trial with re-challenge can help determine causality.

A Danish registry study of 80,000 statin users found no increase in incident depression diagnoses compared with propensity-matched controls, but subgroup analysis for patients under 18 was not powered 24.

Drug Interactions Relevant to Adolescents

Rosuvastatin's low CYP450 involvement results in a shorter interaction list than simvastatin or lovastatin. The interactions that matter most in adolescent clinical practice involve immunosuppressants and HIV antiretrovirals. Those two drug classes overlap with populations that commonly need statin therapy (post-transplant dyslipidemia and HIV-associated metabolic syndrome).

Cyclosporine increases rosuvastatin AUC by 7-fold; concomitant use is contraindicated 25. Adolescent transplant recipients who require a statin should use pravastatin or fluvastatin, which have established post-transplant safety data.

Gemfibrozil doubles rosuvastatin exposure and is contraindicated in combination 26. If triglycerides require separate pharmacotherapy, fenofibrate is an acceptable alternative because it does not meaningfully alter rosuvastatin pharmacokinetics.

Lopinavir-ritonavir and atazanavir-ritonavir increase rosuvastatin AUC by approximately 2-fold; the prescribing information caps the rosuvastatin dose at 10 mg/day in patients taking these agents 27. This is relevant for HIV-positive adolescents on protease inhibitor-based regimens.

Oral contraceptives (ethinyl estradiol/norgestrel) show a 26% increase in ethinyl estradiol AUC and 34% increase in norgestrel AUC with rosuvastatin 40 mg 28. At the 5 to 20 mg doses used in adolescents, the clinical significance is minimal, but clinicians should document the interaction.

Antacids containing aluminum and magnesium hydroxide reduce rosuvastatin plasma concentration by approximately 50% when taken simultaneously 29. Advise dosing rosuvastatin at least 2 hours before antacid use.

Pregnancy Prevention and Contraceptive Counseling

Rosuvastatin is classified as contraindicated in pregnancy. Animal data at supratherapeutic doses showed decreased pup survival and skeletal abnormalities. No adequate human pregnancy trials exist, and the drug should be stopped immediately if pregnancy is confirmed 30.

For all adolescents of childbearing potential, contraceptive counseling is a prerequisite to prescribing. The NHLBI pediatric guidelines explicitly recommend that female patients of reproductive age use effective contraception throughout statin therapy 31. Pregnancy testing at baseline and periodically during treatment is standard practice in most pediatric lipid clinics. Documentation of this counseling protects both patient and provider.

Practical Monitoring Protocol for Prescribers

The following schedule consolidates FDA label requirements and consensus clinic practice:

Before starting therapy: Fasting lipid panel, ALT, AST, CK, fasting glucose, TSH (to rule out secondary causes), Tanner stage documentation, pregnancy test if applicable, and PHQ-A or equivalent mood screen.

At 4 weeks: Phone or telehealth check for myalgia, gastrointestinal symptoms, and mood changes.

At 12 weeks: Fasting lipid panel, ALT, AST, CK (if symptomatic). Assess LDL-C target achievement and tolerability.

Every 6 months: Lipid panel, ALT. Height and weight plotted on growth curves. Tanner stage reassessment annually.

At each visit: Ask about unexplained muscle pain, dark urine, new-onset mood symptoms, and adherence. Reinforce dietary and exercise counseling per NHLBI guidelines 32.

The National Lipid Association recommends continuing statin therapy through adolescence and into adulthood for HeFH patients, with reassessment of dose adequacy at age 18 when adult dosing thresholds apply 33.

When to Reconsider or Discontinue Therapy

Statin discontinuation in adolescents is appropriate under specific, definable circumstances. If CK exceeds 10 times ULN with muscle symptoms, stop the drug and reassess after CK normalizes. If ALT exceeds 3 times ULN on two consecutive draws, discontinue and investigate alternative etiologies (viral hepatitis, MASLD, alcohol). If the patient becomes pregnant, stop immediately.

For adolescents who report muscle symptoms with CK below 4 times ULN, the 2022 European Atherosclerosis Society consensus recommends a structured statin rechallenge: discontinue for 2 to 4 weeks, then restart at half the previous dose or switch to an alternate statin 34. Rosuvastatin's long half-life (19 hours) and lack of active metabolites may confer a lower myalgia burden than simvastatin in head-to-head pediatric comparisons, though this has not been confirmed in a randomized trial.

Adolescents with polygenic hypercholesterolemia (not FH) who achieve sustained LDL-C targets through lifestyle change may be candidates for a supervised statin holiday with lipid re-check at 8 weeks. If LDL-C rebounds above treatment thresholds, therapy should resume.

Baseline fasting glucose should be 95 mg/dL or below in non-obese adolescents starting rosuvastatin. The JUPITER trial in adults (N = 17,802) showed a modest increase in physician-reported diabetes (3.0% vs. 2.4% over 1.9 years median follow-up), an effect attributed in part to baseline risk factors rather than the statin itself 35. No incident diabetes signal was detected in the PLUTO adolescent cohort, though the trial was neither sized nor designed to detect one.